BioTime Hextend
Executive Summary
Plasma volume enhancer received an action letter from FDA Nov. 19 requiring clarification for Hextend application. The company responded that it is "extremely pleased" with the FDA response. No additional clinical trials will be required, according to the company. The Hextend NDA was submitted in March